Related Experiment Video
Updated: May 13, 2026
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Pharmacological treatment of chronic stable angina pectoris
Jason M Tarkin1, Juan Carlos Kaski
1Cardiovascular Sciences Research Centre, University of London, UK.
Insights
New anti-anginal drugs offer improved symptom control for chronic stable angina. Understanding individual disease mechanisms helps select effective pharmacological treatments, improving outcomes for ischaemic heart disease patients.
Area of Science:
- Cardiology
- Pharmacology
- Ischaemic Heart Disease
Background:
- Chronic stable angina is a prevalent manifestation of ischaemic heart disease, significantly impacting quality of life and mortality.
- Pathogenesis involves epicardial coronary artery stenoses and coronary microcirculation dysfunction, leading to myocardial oxygen supply-demand imbalance.
- Despite current therapies, many patients experience persistent angina, necessitating advanced treatment strategies.
Purpose of the Study:
- To review recent advancements in the pharmacological management of chronic stable angina pectoris.
- To highlight the role of understanding individual pathogenic mechanisms in selecting therapeutic strategies.
- To improve clinical outcomes for patients with chronic stable angina.
Main Methods:
- Review of recent pharmacological advances in anti-anginal drug therapy.
- Analysis of novel anti-anginal agents' mechanisms of action and side effect profiles.
- Discussion on integrating traditional and novel treatments for chronic stable angina.
Main Results:
- Several new anti-anginal drugs provide more effective symptom control with fewer side effects.
- Novel agents offer specific mechanisms of action distinct from conventional therapies.
- Combined use of traditional and novel treatments may increase successful medical management.
Conclusions:
- Personalized selection of pharmacological strategies based on pathogenic mechanisms can optimize treatment for chronic stable angina.
- New anti-anginal drugs represent a significant advancement in managing persistent symptoms.
- Integrated therapeutic approaches hold promise for improving long-term outcomes in ischaemic heart disease.
Abstract:
Chronic stable angina is the most common manifestation of ischaemic heart disease in the developed world and is associated with impaired quality of life and increased mortality. The pathogenesis of stable angina is complex and often, albeit not always, involves flow-limiting epicardial coronary artery stenoses (atheromatous plaques) that reduce the ability of the coronary circulation to deliver appropriate blood supply to the myocardium. The coronary microcirculation can also play an important role. An imbalance between myocardial oxygen supply and metabolic oxygen demand causes the symptoms of angina pectoris and represents a major therapeutic target. Rational treatment requires a multi-faceted approach combining lifestyle changes, aggressive management of modifiable coronary artery disease risk factors, pharmacological therapy and myocardial revascularisation when appropriate. Despite modern therapies, many patients continue to suffer from angina. Several new anti-anginal drugs have been introduced that might allow more effective symptom control. These novel agents have specific mechanisms of action and fewer side effects compared to conventional drugs. The combined use of traditional and novel treatments is likely to increase the proportion of patients who are managed successfully with medical therapy alone. This article briefly reviews recent advances in the pharmacological management of chronic stable angina pectoris, highlighting how an understanding of the prevailing pathogenic mechanisms in the individual patient can aid appropriate selection of therapeutic strategies and improve clinical outcome.
Related Concept Videos
01:26Angina IV: Management
01:20Angina V: Nursing Management
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:27Angina II: Classification
01:27Coronary Artery Disease V: Interprofessional Care